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Abstract
Background. Renal re-transplants are increasing in num-
ber, due to many first renal transplant patients coming
back to dialysis treatment. There are controversial opinions
about the evolution of these re-transplanted patients. The
aim of our study is to analyse the prognosis of patients
and grafts under a renal re-transplant.
Methods. This was a retrospective study of 579 renal re-
transplants realized in 15 Spanish different centres in the
years 1990, 1994, 1998 and 2002 including all renal re-
transplants realized in the above-mentioned centres during
the same periods.
Results. During the follow-up period, 8.81% of patients
died. The actuarial patient survival was 85% at 10 years
and 80% at 15 years. Principal reasons of death were the
same as normal for the renal transplanted patient: cardio-
vascular (30.77%), infectious (13.46%) and neoplastic
(13.46%). During the period of follow-up, 28.6% of the
grafts were lost. The actuarial graft survival was 75% at
10 years and 58% at 15 years. Causes of graft loss are very
similar to those described in literature.
Conclusion. Renal re-transplant is a kind of substitute re-
nal treatment with excellent clinical results that allow to
take it as a first-order modality of treatment when the first
renal transplant has failed.
Keywords: Renal re-transplant
Introduction
Renal re-transplant is a situation in which a worse result is
expectedcomparedtothefirsttransplant,duetodiversefac-
tors among which it would be necessary to mention the pos-
sibility of more anti-human leucocyte antigen (HLA)
antibodies existing in the recipient to possible donors, a
worse general condition from the cardiovascular point of
view, the advanced age of both donor and recipient, etc.
The aim of this work is to review the renal re-transplants
done in Spain in the period 1990–2002, specifically in the
years 1990, 1994, 1998 and 2002, in order to be able to de-
termine if patient and graft survival are good as well as to
realize a description of their evolution.
Materials and methods
The sample was formed of 579 renal re-transplants realized in 15 Spanish
different centres in the years 1990, 1994, 1998 and 2002. This retrospec-
tive study included all the renal re-transplants realized in the above-
mentioned centres during those periods. Their stratification per year
was as follows: 1990 (13.13%), 1994 (22.63%), 1998 (38.75%) and
2002 (28.50%). Nevertheless, the differences in percentage do not equate
to an increase of the proportion of re-transplants, since when we analyse
the percentage that the re-transplants represent with regard to the number
of the first realized transplants every year, the proportions are very
similar: 1990 (9.2%), 1994 (12.2%), 1998 (13.9%) and 2002 (12.4%).
The mean age of the donors was 40.31 ± 16 years (12–77) and that of
the recipients 41.86 ± 12 years (19–75), the mean weight of the recipients
being 63.19 ± 12.13 kg. As for gender, the donors were men in 66.49%
(women 33.51%), and the recipients were men in 59.07% (women
40.93%) (Table 1).
The mean of the quantitative variables during the first year has been
calculated with the values obtained at the time of transplant, Month 1,
Month 3 and Year 1 post-transplant. The curves of survival have been
obtained by the Kaplan–Meier method.
Results
(i) Primary disease. The most predominant primary dis-
ease in the recipients was chronic glomerulonephritis
(40%), followed by tubulointerstitial nephropathies
(15%), polycystic kidney disease (7.5%), nephroan-
giosclerosis (7.5%) and diabetes mellitus (5%). The
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scribed by renal pathology records of other countries
[1,2].
(ii) Time on substitute renal treatment. The mean time
that they were under any modality of substitute renal
treatment was 8.19 ± 5.84 years (0–29.44). Of the
patients, 92.45% were on treatment with haemo-
dialysis and 7.55% on peritoneal dialysis prior to
re-transplant.
(iii) HLA incompatibilities and anti-HLA antibodies. It
was always taken into account to have a maximum
HLA compatibility in case of renal re-transplant.
Gjertson [3] had recently described the importance
of a good HLA compatibility, especially DR in cases
of renal re-transplant. In our series, the average was
three HLA incompatibilities (1 for HLA-A, 1.2 HLA-
B and 0.8 HLA-DR). The maximum percentage of
anti-HLA antibodies was 31.99 ± 33.46% (0–100),
and the last pre-transplant anti-HLA was 14.97 ±
24.59% (0–100). Of the patients, 53% had 0% of an-
ti-HLA antibodies at the time of re-transplant.
(iv) Type of donor. In 97% of cases, the donor was ca-
daveric, with 3% living donors. Of those cadaveric
donors, in 51%, the reason of death was a craneoen-
cephalic trauma, and in 49%, it was a vascular cere-
bral accident.
(v) Viral status. With regard to the hepatitis C virus
(HCV), 3.4% of the donors and 38.6% of the recipi-
ents had positive antibodies. As for the hepatitis B
virus (HBV), 0.8% of donors and 1% of the recipi-
ents had positive antibodies.
(vi) Initial immunosuppressive treatment. It was realized
with steroids in 97.2% of the cases, cyclosporine
(63%), mycophenolate mofetil (51.5%), tacrolimus
(31.8%), azathioprine (30.4%), and sirolimus
(2.1%), reflecting the general evolution of the immu-
nosuppressive treatment in the transplant population
over recent years. The most used antibodies in induc-
tion treatments were OKT3 (14.9%), anti-CD25
(10.2%) and ATG (5%). The steroids were with-
drawn in the first 3 months in 0.36% of the cases.
Some authors have described that the introduction
of mycophenolate mofetil in the protocols of immu-
nosuppression together with the use of flow cytome-
try cross-match have been decisive in the good
results of the renal re-transplant in recent years [4].
(vii) Acute tubular necrosis. This was present in 39.25%
of the cases. It is a result even better than described
for certain series of patients without re-transplant [5].
(viii) Acute rejection. This happened in 29% of cases, be-
ing treated only by steroids in 67.68% of cases and
by steroids with more antibodies in 17.68%. The re-
nal biopsy done in case of acute rejection showed the
Banff's following gradation: Ia (35.53%), Ib (7.89%),
IIa (31.58%), IIb (13.16%), III (11.84%). Graft loss
Table 1. Demographics of donors and re-transplanted patients
Donor Recipient
Age (years) 40.31 ± 16 41.86 ± 12
Gender % (male/female) 66.49/33.51 59.07/40.93
Weight (kg) ND 63.19 ± 12.13
IMC (kg/m²) ND 23.16 ± 3.82
Table 2. Renal biopsy results
Renal biopsy results %
CAN Ia 6.54
CAN Ib 4.58
CAN IIa 11.76
CAN Iib 6.54
CAN IIIa 5.88
CAN IIIb 2.27
Acute rejection 3.92
Recurrence of primary nephropathy 2.61
Transplant glomerulopathy 6.54
De novo glomerulonephritis 5.23
Other 6.54
SCR14 SCR12 SCR10 SCR9 SCR8 SCR7 SCR6 SCR5 SCR4 SCR3 SCR2 SCR1 SCR3m
M
e
a
n
 
p
l
a
s
m
a
t
i
c
 
c
r
e
a
t
i
n
i
n
e
2,50
2,00
1,50
1,00
0,50
0,00
Evolution of plasmatic creatinine (mg/dL)
Years after retransplant
SCR15 SCR13 SCR11
Fig. 1. Evolution of plasmatic creatinine in renal re-transplanted patients.
ii38 L. Guirado et al.for acute rejection happened in 3.8% of the re-
transplanted patients.
(ix) Renal biopsy. In Spain, protocol biopsies were not
practised in the years of the study, but always were
done for clinical reasons. Renal biopsy was practised
in 51% of the patients, principal reasons being wors-
ening of renal function (50.33%) and proteinuria
(17.65%). Results of renal biopsy appear in Table 2.
As can also be seen, the most frequent find was inter-
stitialfibrosiswithtubularatrophyofdifferentdegree.
(x) Renal function and proteinuria. Patients were kept
stable along the follow-up as shown in Figure 1.
One year after transplant, 30.4% of patients had a
plasmatic creatinine between 0.5 and 1.2 mg/dL,
50% between 1.3 and 2 mg/dL, 14.4% between 2.1
and 3 mg/dL and 5.1% >3 mg/dL.
(xi) Patient survival. During the follow-up period, 8.81%
of patients died. The actuarial survival of the patient
was at 10 years of 85% and 80% at 15 years. Principal
reasons of death were the same as normal for renal
transplanted patients: cardiovascular (30.77%), infec-
tious (13.46%) and neoplastic (13.46%) (Figure 2).
(xii) Graft survival. During the follow-up period, 28.6%
of the grafts were lost. The actuarial survival of the
graft was 75% at 10 years and 58% at 15 years. Prin-
cipal reasons for this graft loss are detailed in Ta-
ble 3. As can also be seen, they are very similar to
previous descriptions in the literature [6,7](Figure 3).
(xiii) Cytomegalovirus infection. This was detected in
20.72% of cases. The methods of detection were di-
verse depending on the centres and the epoch (pp65,
CMV-PCR…). Of the patients, 37.9% had received
some type of prevention for cytomegalovirus due to
being considered patients of risk (positive donor/
negative recipient, treatment with high doses of ster-
oids, etc.).
(xiv) Surgical complications. Of the patients, 12.5% need-
ed re-intervention, the most frequent reasons being
ureteral obstruction, urinary leakage and surgical
haemorrhage. The above-mentioned information
was also coincidental with the general series of trans-
planted patients in our country.
Discussion
Previous results take us to the conclusion that the results of
renal re-transplant in Spain are excellent, showing patient
and graft survivals at 10 years of 85% and 75%, respective-
ly, similar to those undergoing a first transplant, and even
better than described in general series of other countries
[2]. Some authors have recently described that, in patients
with standard immunological risk [8] and even in groups
ofhighrisksuchastheAfro-American population[9],renal
re-transplant gives identical results to the first transplant.
Some authors obtain the same conclusions regarding the
goodevolutionofrenalre-transplantsandrecommenditun-
reservedly (10). In our data, renal function was kept stable
throughout the time period, and the reasons of graft loss
would be the same as those of the general series of the first
transplants [6]. The percentage of acute tubular necrosis
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Fig. 2. Cumulative patient survival after renal re-transplant.
Table 3. Causes of graft loss
Causes of graft loss %
Biopsy-proven chronic allograft nephropathy 27.22
Not biopsy-proven chronic allograft nephropathy 27.25
Death with functioning kidney 19.62
Acute rejection 3.8
De novo glomerulonephritis 3.8
Recurrence of primary disease 3.16
Bad adherence to treatment 1
Other 5.7
Results of renal re-transplant in Spain ii39(39.25%) is superior to the current one when the donor
and recipient mean ages are about 40 years old, and there
is also a higher percentage of acute rejection than the
current one, though it is easily understandable as a conse-
quence of the current immunosuppressive medication. It is
necessary to emphasize that 51% of these re-transplants
have been under biopsy throughout an important period of
follow-up. The most common find of the biopsy will be the
non-specific fibrosis and tubular atrophy.
It is necessary to conclude that renal re-transplant is a
kind of substitute renal treatment with excellent clinical re-
sults that allow to take it as a first-order modality of treat-
ment when the first renal transplant has failed.
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Fig. 3. Cumulative graft survival after renal re-transplant.
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